3158 Department of Psychiatry, University of Alberta, Edmonton, Canada.
Department of Dermatology and Venereology, Syrian Arab Red Crescent Hospital, Ministry of Health, Damascus, Syria.
J Cutan Med Surg. 2023 Mar-Apr;27(2):140-149. doi: 10.1177/12034754231155888. Epub 2023 Feb 20.
The lack of clinical guidelines for the treatment of primary psychodermatologic disorders (PPDs) hinders the delivery of optimal care to patients. The review aimed to identify, appraise, and summarize the currently available evidence about the safety and effectiveness of pharmacological management of PPDs through randomized controlled trials (RCTs).
The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRIMSA) statement and the Global Evidence Mapping Initiative guidance were followed. Medline, Embase, PsycInfo, Cochrane and Scopus were searched, and two reviewers independently completed article review, data extraction, and quality assessment.
Among 2618 unique studies, full texts of 83 were reviewed and 21 RCTs were included. Five PDDs were identified: trichotillomania ( = 12), pathologic skin picking ( = 5), nail biting ( = 2), delusional parasitosis ( = 1), and dermatitis from compulsive hand washing ( = 1). Seven different classes of medications were investigated: SSRIs (i.e., fluoxetine, sertraline, and citalopram), tricyclic antidepressants (i.e., clomipramine and desipramine), antipsychotics (i.e., olanzapine and pimozide), anticonvulsant (i.e., lamotrigine), N-acetylcysteine, inositol, and milk thistle. RCT-derived evidence supports the use of antidepressants in trichotillomania (sertraline and clomipramine), pathologic skin picking (fluoxetine), pathologic nail biting and dermatitis from compulsive hand washing (clomipramine or desipramine); antipsychotics in trichotillomania (olanzapine) and delusional parasitosis (pimozide); N-acetyl cysteine in trichotillomania and skin picking.
Few pharmacotherapies for primary psychodermatologic disorders are assessed through controlled trials in the literature. This review serves as a roadmap for researchers and clinicians to reach informed decisions with current evidence, and to build on it to establish guidelines in the future.
原发性精神皮肤病(PPD)的治疗缺乏临床指南,这阻碍了为患者提供最佳治疗。本综述旨在通过随机对照试验(RCT),确定、评估和总结目前关于 PPD 药物治疗安全性和有效性的现有证据。
我们遵循了《系统评价和荟萃分析的首选报告项目》(PRIMSA)声明和全球证据映射倡议指南。检索了 Medline、Embase、PsycInfo、Cochrane 和 Scopus,两位审查员独立完成了文章审查、数据提取和质量评估。
在 2618 项独特的研究中,我们对 83 项研究的全文进行了审查,纳入了 21 项 RCT。确定了 5 种 PPD:拔毛癖( = 12)、病理性皮肤搔抓( = 5)、咬甲癖( = 2)、妄想性寄生虫病( = 1)和强迫性洗手引起的皮炎( = 1)。研究了 7 种不同类别的药物:SSRIs(即氟西汀、舍曲林和西酞普兰)、三环类抗抑郁药(即氯米帕明和去甲丙咪嗪)、抗精神病药(即奥氮平和匹莫齐特)、抗惊厥药(即拉莫三嗪)、N-乙酰半胱氨酸、肌醇和奶蓟草。RCT 衍生的证据支持在拔毛癖(舍曲林和氯米帕明)、病理性皮肤搔抓(氟西汀)、病理性咬甲和强迫性洗手引起的皮炎(氯米帕明或去甲丙咪嗪)中使用抗抑郁药;在拔毛癖(奥氮平)和妄想性寄生虫病(匹莫齐特)中使用抗精神病药;在拔毛癖和皮肤搔抓中使用 N-乙酰半胱氨酸。
文献中很少有针对原发性精神皮肤病的药物治疗进行对照试验评估。本综述为研究人员和临床医生提供了一个路线图,以便根据现有证据做出明智的决策,并在此基础上为未来制定指南。